<DOC>
	<DOCNO>NCT01486017</DOCNO>
	<brief_summary>The purpose study determine relative bioavailability pharmacokinetic profile three strength new tablet formulation ASP015K evaluate safety tolerability single dose three different strength new tablet formulation .</brief_summary>
	<brief_title>A Single Oral Dose Study ASP015K Healthy Volunteers Assessing Relative Bioavailability Across Three Tablet Strengths From New Formulation ASP015K</brief_title>
	<detailed_description>Eligible subject admit Day-1 remain confined unit 16 day . Each subject receive single dose study drug per define treatment period morning Day 1 , Day 6 Day11 . There minimum 5 day consecutive dose group . Any subject discontinuing study prior completion end study evaluation complete .</detailed_description>
	<criteria>Subject weigh least 45 kg body mass index ( BMI ) 1832 kg/m2 Male subject agree sexual abstinence , surgically sterile use medically acceptable method prevent pregnancy agree continue use method 90 day last dose study drug administration Male subject agrees donate sperm 90 day dose study drug administration Female subject surgically sterile postmenopausal pregnant lactating Subject 's 12lead electrocardiogram ( ECG ) normal Subject must capable swallow multiple tablet Subject previous history clinically significant gastrointestinal , neurological , renal , hepatic , pulmonary , metabolic , cardiovascular , psychiatric , endocrine , hematological disorder disease , malignancy exclude nonmelanoma skin cancer medical condition Subject major GI surgery ( colectomy , cholecystectomy , etc ) Subject history consume 14 unit alcoholic beverage per week history alcoholism drug/chemical/ substance abuse within past 2 year Subject has/had symptomatic , viral , bacterial ( include upper respiratory infection ) , fungal ( noncutaneous ) infection within 1 week Subject positive test hepatitis C antibody , positive test hepatitis B surface antigen ( HBsAg ) , positive hepatitis B core antibody Subject history human immunodeficiency virus ( HIV ) antibody Subject positive tuberculosis ( TB ) skin test , Quantiferon Gold test TSPOTÂ® test Subject receive vaccine within 60 day Subject receive experimental agent within 30 day Subject absolute neutrophil count ( ANC ) &lt; 2500 cells/mm3 Subject significant blood loss , donate one unit ( 450 mL ) blood , receive transfusion blood blood product within 60 day donate plasma within 7 day Subject history smoking use tobaccocontaining product nicotine nicotinecontaining product past six month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>ASP015K</keyword>
	<keyword>healthy subject</keyword>
	<keyword>bioavailability</keyword>
	<keyword>rheumatoid arthritis</keyword>
	<keyword>psoriasis</keyword>
	<keyword>transplantation</keyword>
</DOC>